Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tema Obesity & Cardiometabolic ETF (NQ: HRTS )

31.35 +0.13 (+0.42%)
Streaming Delayed Price Updated: 2:50 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,766
Open 31.13
Bid (Size) 31.23 (1)
Ask (Size) 31.34 (7)
Prev. Close 31.22
Today's Range 31.13 - 31.49
52wk Range 26.26 - 35.58
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea. 
Via Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
Two dominant investing themes over the past year have been AI and weight-loss drugs. 
Via Talk Markets
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence

Performance

YTD
+2.27%
+2.27%
1 Month
-7.30%
-7.30%
3 Month
-2.01%
-2.01%
6 Month
+17.75%
+17.75%
1 Year
+17.75%
+17.75%

More News

Read More
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Via Investor's Business Daily
Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
Via Benzinga
Topics ETFs
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.